AstraZeneca PLC (AZN) Aandelenanalyse

Bedrijfsoverzicht

AstraZeneca PLC is a leading biopharmaceutical entity dedicated to the discovery, development, manufacture, and commercialization of prescription medicines designed to treat a wide range of conditions. The company operates within the Healthcare sector, specifically classified under the industry of Drug Manufacturers - General, which positions it as a critical player in the global provision of therapeutic solutions. With a substantial market capitalization of $316.30B and an annual revenue of $58.74B, the firm demonstrates significant economic weight in the pharmaceutical landscape. Furthermore, the organization employs 96100 individuals across its global operations, reflecting the extensive scale required to support its complex research and commercialization activities. These financial dimensions, particularly the multi-trillion dollar valuation relative to its revenue stream, indicate that the company commands a premium position in the market, suggesting high investor confidence in its established portfolio and future pipeline capabilities within the highly regulated drug manufacturing environment.

Financiële gezondheid

The company reported a total revenue of $58.74B and a net income of $10.23B for the trailing twelve months, while EBITDA stood at $19.28B. The substantial difference between the revenue figure and the net income reveals a robust cost structure where operating expenses and taxes account for approximately 82.6% of total sales, yet the remaining earnings still generate significant profit. AstraZeneca generated $7.87B in free cash flow, a metric that provides the organization with considerable financial flexibility to fund ongoing research programs, acquire new assets, or return capital to shareholders without relying on external financing. The gross margin stands at an impressive 81.7%, indicating high pricing power and efficient production costs relative to the cost of goods sold. Operating margins are recorded at 21.6%, which reflects the efficiency of the company's core business operations before interest and taxes, while the profit margin sits at 17.4%, demonstrating the final percentage of revenue that translates into net earnings. Regarding the balance sheet, the company holds $5.72B in cash against a total debt load of $29.70B, resulting in a debt-to-equity ratio of 60.97%, which suggests a leveraged balance sheet typical for capital-intensive pharmaceutical firms that require significant investment in clinical trials and manufacturing capacity. The current ratio is 0.94, indicating that the company's current assets are slightly lower than its current liabilities, which points to a tight short-term liquidity position that requires careful management of working capital. Return on Equity is calculated at 22.8%, showing that the company generates substantial returns on the shareholder capital invested, while the return on assets is 8.2%, which reveals the overall efficiency of the company in utilizing its asset base to generate profits relative to the total asset value.

Waarderingsbeoordeling

AstraZeneca PLC trades with a trailing P/E ratio of 31.15 and a forward P/E of 25.67. The notable difference between the trailing and forward multiples implies that the market expects earnings growth in the future that will significantly compress the valuation multiple over time. The price-to-book ratio is 6.50, indicating that the market values the company's equity at a significant premium of over six times its net asset book value, likely reflecting the high value of intangible assets such as intellectual property and pipeline potential. Alternative valuation metrics show a price-to-sales ratio of 5.38 and an EV/EBITDA of 17.66, which suggest that the company is priced for high growth and strong earnings power relative to its size. The stock has a 52-week high of $212.71 and a 52-week low of $132.32, providing a clear trading range for analysis of recent price movements. Without the specific current share price provided in the available facts, the exact percentage deviation from the 52-week high cannot be calculated; however, the range itself demonstrates the volatility experienced over the past year. The beta value is 0.28, which indicates that the stock's price volatility is significantly lower than the broader market, making it a less sensitive investment to general market swings compared to high-beta technology or consumer discretionary stocks.

Growth & Income

For the trailing twelve months, revenue growth is recorded at 4.1% year-over-year, while earnings growth is 53.9% year-over-year. The disparity between these two figures indicates that earnings are growing at a pace far exceeding revenue expansion, which implies strong operational leverage and potentially favorable pricing dynamics or cost efficiencies that are boosting profitability disproportionately to top-line sales. As a dividend payer, the company offers a dividend yield of 1.6% with a payout ratio of 47.9%. This payout ratio is generally considered sustainable given the company's robust earnings growth and strong cash flow generation, allowing it to maintain or potentially increase dividends while continuing to invest in its development pipeline. The combination of moderate revenue growth and exceptional earnings acceleration, alongside a reliable dividend yield, creates a hybrid profile that offers both income generation and capital appreciation potential. This overall growth and income profile positions AstraZeneca as a compounder capable of delivering shareholder value through both retained earnings reinvestment and consistent cash distributions.